Episode 384: ASCO GU Preview

Dr. Silke Gillessen of the Oncology Institute of Southern Switzerland joins Brian and Tom to discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025, such as new data from TALAPRO-2 and a trial investigating metastasis-directed therapy with standard therapy for oligometastatic castration-resistant prostate cancer.